Coronavirus Trend Helps Improve Krka’s EBIT By 85%
As Prescription Pharmaceutical Sales Shoot Up In Q1
Executive Summary
Slovenian firm Krka saw an increased demand for its prescription product portfolio during the quarter, which boosted group sales by more than a fifth. The company’s bottom line was a slightly more complex tale, as currency exposure in Russia wiped out significant gains in Krka’s EBIT.